These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32783751)

  • 1. Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer
    Wang J; Liu T; Chen J
    Cancer Biother Radiopharm; 2021 Nov; 36(9):774-782. PubMed ID: 32783751
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists.
    Backhaus PS; Veinalde R; Hartmann L; Dunder JE; Jeworowski LM; Albert J; Hoyler B; Poth T; Jäger D; Ungerechts G; Engeland CE
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31623390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.
    Veinalde R; Grossardt C; Hartmann L; Bourgeois-Daigneault MC; Bell JC; Jäger D; von Kalle C; Ungerechts G; Engeland CE
    Oncoimmunology; 2017; 6(4):e1285992. PubMed ID: 28507792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: "Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer
    Engeland CE
    Cancer Biother Radiopharm; 2021 Feb; 36(1):106-107. PubMed ID: 33259718
    [No Abstract]   [Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
    Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
    BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
    Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
    J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.
    Ruotsalainen JJ; Kaikkonen MU; Niittykoski M; Martikainen MW; Lemay CG; Cox J; De Silva NS; Kus A; Falls TJ; Diallo JS; Le Boeuf F; Bell JC; Ylä-Herttuala S; Hinkkanen AE; Vähä-Koskela MJ
    Gene Ther; 2015 Jan; 22(1):65-75. PubMed ID: 25231172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
    Hoffmann D; Bayer W; Wildner O
    Hum Gene Ther; 2007 May; 18(5):435-50. PubMed ID: 17518612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
    Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
    Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
    Choi IK; Li Y; Oh E; Kim J; Yun CO
    PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.